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A commentary on
Aiming for Study Comparability in Parkinson’s Disease: Proposal for a Modular Set of
Biomarker Assessments to be Used in Longitudinal Studies
by Lerche, S., Heinzel, S., Alves, G. W., Barone, P., Behnke, S., Ben-Shlomo, Y., et al. (2016). Front.
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INTRODUCTION
We read the conclusions of Lerche et al. (2016) with great interest. Various definitions exist in
the literature for biological markers (often shortened to biomarkers). In medicine, a biomarker
may refer to an indicator based upon which an inference about the person’s health can be made.
The National Health Institute’s Biomarkers Definitions Working Group (Biomarkers Definitions
Working Group, 2001) defines a biomarker as “a characteristic that is objectively measured and
evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological
responses to a therapeutic intervention.”
Despite the recent interest in finding biomarkers for Parkinson’s disease (PD; as evident
from the number of “Parkinson’s disease biomarker” articles indexed by the MEDLINE R©
Database; see Figure 1), an acceptable biomarker for PD remains to be elusive. Given the
complexity underpinning PD’s pathological processes, a useful single biomarker is unlikely to
encompass the plethora of disease facets. However, the diverse features of PD’s aetiological process
and manifestations lend it particularly suited to have a number of biomarkers (of different
categories and types) that serve distinct purposes at various stages of the disease.
CHALLENGES FACING PD BIOMARKER RESEARCH
As with other neurodegenerative disorders, several hurdles face biomarker discovery in PD. Such
challenges include the general complexity of the human CNS, limited access and availability
of tissue for histological diagnosis during the patient’s lifetime and the restricted number of
clinical end-points and the lack of validation models for present ones (Dunckley et al., 2005).
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FIGURE 1 | Increasing numbers of PD biomarker-related articles, as indexed by MEDLINE® as of January 2016, are appearing in the literature.
Added to these general obstacles are the diagnostic
uncertainties surrounding PD, including disease
heterogeneity and the potential for atypical parkinsonian
syndromes.
The multiplicity of disease aspects of PD make it difficult
for a single all-purpose biomarker to ever exist. This is evident
from the current lack of such a “Holy Grail” biomarker
to date. By the same token, “reductionist”-type biomarkers
focusing on single aspects of PD molecular neuropathology
are unlikely to be overly clinically useful in the general
schema of disease (Mielke and Maetzler, 2014). It seems,
therefore, that several biomarkers of different types may
be utilized in conjunction to identify the person’s disease
stage.
Taking PD diagnosis as an example, no one single biomarker
to date has demonstrated perfect sensitivity and specificity; even
post-mortem pathological examinations can be inconclusive at
times (Lees et al., 2009; Berg et al., 2013). Instead, the suggested
tier-based system of different types of biomarkers (e.g., clinical
assessment by a specialist, biofluid analysis, genetic testing
and/or imaging studies) used in concert is much more likely
to yield much needed diagnostic accuracy (Streffer et al., 2012;
Schlossmacher and Mollenhauer, 2014).
FUTURE DIRECTIONS
Much research has gone into obtaining new prospectively-
collected data (e.g., The Parkinson Progression Marker
Initiative Marek, 2011), as well as examining archived biofluid
and tissue specimens [e.g., Honolulu Asian Aging Study
(Abbott et al., 2016)]. However, much still remains to be
desired.
The ongoing collaborative efforts are hoped to generate large
datasets and standardized resources which are publicly available.
The next major step is the proper utilization of such data
mines. This would involve using current bioinformatics and
technological advances (i.e., -omics) to thoroughly evaluate the
data, as well as making use of integration models which can
capture interplay between biomarkers that would have otherwise
been hidden (Azuaje, 2011).
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